{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:24:41Z","timestamp":1788121481561,"version":"build-2803163510"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"MinCiencias","award":["RC-007-2017"],"award-info":[{"award-number":["RC-007-2017"]}]},{"name":"MinCiencias","award":["110274558597"],"award-info":[{"award-number":["110274558597"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejmech.2020.112647","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T12:28:14Z","timestamp":1594816094000},"page":"112647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus"],"prefix":"10.1016","volume":"203","author":[{"given":"Vladimir V.","family":"Kouznetsov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112647_bib1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2020.112647_bib2","series-title":"Severe acute respiratory syndrome-related coronavirus-The species and its viruses, a statement of the Coronavirus Study Group","author":"Gorbalenya","year":"2020"},{"issue":"5624","key":"10.1016\/j.ejmech.2020.112647_bib3","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1085952","article-title":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome","volume":"300","author":"Rota","year":"2003","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.ejmech.2020.112647_bib4","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112647_bib5","first-page":"63","article-title":"Corona virus SARS-CoV-2 disease COVID-19: infection, prevention and clinical advances of the prospective chemical drug therapeutics","volume":"7","author":"Chhikara","year":"2020","journal-title":"Chem. Biol. Lett."},{"key":"10.1016\/j.ejmech.2020.112647_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J.\u00a0Autoimmun."},{"key":"10.1016\/j.ejmech.2020.112647_bib7","first-page":"248","article-title":"An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)","volume":"5","author":"Tang","year":"2020","journal-title":"Infect. Dis. Model."},{"key":"10.1016\/j.ejmech.2020.112647_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00001432-200404000-00013","article-title":"Severe acute respiratory syndrome","volume":"17","author":"Wang","year":"2004","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.ejmech.2020.112647_bib11","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/nm.3985","article-title":"A\u00a0SARS-like cluster of circulating bat coronaviruses shows potential for human emergence","volume":"21","author":"Menachery","year":"2015","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.ejmech.2020.112647_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"issue":"7798","key":"10.1016\/j.ejmech.2020.112647_bib13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A\u00a0pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112647_bib14","series-title":"Wuhan Seafood Market Pneumonia Virus Isolate Wuhan-Hu-1, Complete Genome. Nucleotide, National Center for Biotechnology Information (NCBI)","year":"2009"},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib15","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/0022-1317-81-4-853","article-title":"Virus-encoded proteinases and proteolytic processing in the Nidovirales","volume":"81","author":"Ziebuhr","year":"2000","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ejmech.2020.112647_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARScoronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"Baez-Santos","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2020.112647_bib17","doi-asserted-by":"crossref","unstructured":"Y. Gao, L. Yan, Y. Huang, F. Liu, Y. Zhao, L. Cao, Structure of the RNA-dependent RNA polymerase from COVID-19 virus, Science 368 (6492) 779-782.","DOI":"10.1126\/science.abb7498"},{"issue":"3","key":"10.1016\/j.ejmech.2020.112647_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV - a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"6485","key":"10.1016\/j.ejmech.2020.112647_bib19","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"issue":"6489","key":"10.1016\/j.ejmech.2020.112647_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ejmech.2020.112647_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112647_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.virol.2014.10.006","article-title":"Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry","volume":"471","author":"Song","year":"2014","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.ejmech.2020.112647_bib23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/acschemneuro.0c00122","article-title":"Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host\u2013virus interaction, and proposed neurotropic mechanisms","volume":"11","author":"Baig","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"issue":"10223","key":"10.1016\/j.ejmech.2020.112647_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejmech.2020.112647_bib26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","volume":"10","author":"Li","year":"2020","journal-title":"J.\u00a0Pharm. Anal."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112647_bib27","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J.\u00a0Biol. Regul. Homeost. Agents"},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00187-20","article-title":"The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options","volume":"58","author":"Khan","year":"2020","journal-title":"J.\u00a0Clin. Microbiol."},{"issue":"10","key":"10.1016\/j.ejmech.2020.112647_bib29","article-title":"COVID-19: a promising cure for the global panic","volume":"725","author":"Vellingiri","year":"2020","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.ejmech.2020.112647_bib30","series-title":"COVID-19 Trials Registered up to 8 March 2020-an Analysis of 382 Studies","author":"Aronson","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112647_bib31","doi-asserted-by":"crossref","unstructured":"J. Wang, Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study, J. Chem. Inf. Model. 60 (6) 3277\u20133286.","DOI":"10.1021\/acs.jcim.0c00179"},{"key":"10.1016\/j.ejmech.2020.112647_bib32","series-title":"Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface","author":"Smith","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112647_bib33","first-page":"26","article-title":"Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants","author":"ul Qamar","year":"2020","journal-title":"J.\u00a0Pharm. Anal."},{"key":"10.1016\/j.ejmech.2020.112647_bib34","series-title":"Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches","author":"Zhavoronkov","year":"2020"},{"key":"10.1016\/j.ejmech.2020.112647_bib35","series-title":"Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of COVID-19 Main Protease: A Virtual Drug Repurposing Study","author":"Durdagi","year":"2020"},{"issue":"1","key":"10.1016\/j.ejmech.2020.112647_bib36","article-title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","volume":"248","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2020.112647_bib37","article-title":"Identification of FDA approved drugs targeting COVID-19 virus by structure-based drug repositioning","author":"Farag","year":"2020","journal-title":"ChemRxiv"},{"issue":"6485","key":"10.1016\/j.ejmech.2020.112647_bib38","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","article-title":"Race to find COVID-19 treatments accelerates","volume":"367","author":"Kupferschmidt","year":"2020","journal-title":"Sciences"},{"issue":"9","key":"10.1016\/j.ejmech.2020.112647_bib39","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112647_bib40","article-title":"Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication","author":"Zhang","year":"2020","journal-title":"BioRxiv"},{"issue":"3","key":"10.1016\/j.ejmech.2020.112647_bib41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib42","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib44","first-page":"928","article-title":"D\u00e9j\u00e0 vu: stimulating open drug discovery for SARS-CoV-2, Drug Discov","volume":"25","author":"Ekins","year":"2020","journal-title":"Today Off."},{"key":"10.1016\/j.ejmech.2020.112647_bib45","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"20","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med. Maladies Infect."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112647_bib47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.ejmech.2020.112647_bib48","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favor of remdesivir for treating SARS-CoV-2 infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112647_bib50","article-title":"Remdesivir as a possible therapeutic option for the COVID-19, Travel Med","volume":"34","author":"Al-Tawfiq","year":"2020","journal-title":"Inf. Disp."},{"issue":"396","key":"10.1016\/j.ejmech.2020.112647_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib52","first-page":"1023","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review","volume":"4","author":"Chandwani","year":"2008","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"14","key":"10.1016\/j.ejmech.2020.112647_bib53","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2165\/11204950-000000000-00000","volume":"70","author":"Croxtall","year":"2010","journal-title":"Lopinavir\/ritonavir, Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2020.112647_bib54","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.ejmech.2020.112647_bib55","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Japan Acad., Series B"},{"issue":"24","key":"10.1016\/j.ejmech.2020.112647_bib56","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2174\/0929867324666170911162331","article-title":"Reappraisal of antimalarials in interferonopathies: new perspectives for old drugs","volume":"25","author":"Piscianz","year":"2018","journal-title":"Curr. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2020.112647_bib57","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40261-018-0656-y","article-title":"Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review","volume":"38","author":"Plantone","year":"2018","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejmech.2020.112647_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2020.112647_bib59","doi-asserted-by":"crossref","DOI":"10.7326\/M20-1334","article-title":"Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know","author":"Yazdany","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2020.112647_bib60","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1070\/RCR4791","article-title":"Arbidol: a quarter-century after. Past, present and future of the original Russian antiviral","volume":"87","author":"Balakin","year":"2018","journal-title":"Russ. Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.112647_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2020.112647_bib62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.trsl.2019.12.002","article-title":"Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model","volume":"218","author":"Toots","year":"2020","journal-title":"Transl. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112647_bib64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112647_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1586\/eri.09.5","article-title":"Ribavirin in chronic hepatitis C: past and future","volume":"7","author":"Loustaud-Ratti","year":"2009","journal-title":"Expert Rev. Anti-infect. Ther."},{"issue":"9","key":"10.1016\/j.ejmech.2020.112647_bib66","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2174\/138955710791608316","article-title":"Triazole nucleoside derivatives bearing aryl functionalities on the nucleobases show antiviral and anticancer activity","volume":"10","author":"Xia","year":"2010","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112647_bib67","first-page":"30","article-title":"Novel coronavirus treatment with ribavirin: groundwork for evaluation concerning COVID-19","author":"Khalili","year":"2020","journal-title":"J.\u00a0Med. Virol."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112647_bib68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-015-0351-8","article-title":"Ruxolitinib: a review of its use in patients with myelofibrosis","volume":"75","author":"Plosker","year":"2015","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2020.112647_bib69","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112647_bib70","first-page":"51","article-title":"Efficacy of ingavirin in adults with influenza","volume":"81","author":"Kolobukhina","year":"2009","journal-title":"Ter. Arkh."},{"issue":"7\u20138","key":"10.1016\/j.ejmech.2020.112647_bib71","first-page":"27","article-title":"Therapeutic efficacy of Ingavirin, a new domestic formulation against influenza A virus (H3N2)","volume":"53","author":"Loginova","year":"2008","journal-title":"Antib. Khimioterap."},{"key":"10.1016\/j.ejmech.2020.112647_bib72","author":"Ingavirin"},{"issue":"2","key":"10.1016\/j.ejmech.2020.112647_bib73","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol. Therapeut."},{"issue":"10","key":"10.1016\/j.ejmech.2020.112647_bib74","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41429-019-0204-x","article-title":"Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09 virus infection by interfering with virus internalization process","volume":"72","author":"Tran","year":"2019","journal-title":"J.\u00a0Antibiot."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112647_bib75","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5582\/bst.2020.03058","article-title":"Macrolide treatment for COVID-19: will this be the way forward?","volume":"14","author":"Ohe","year":"2020","journal-title":"BioScience Trends"},{"issue":"11","key":"10.1016\/j.ejmech.2020.112647_bib76","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.pt.2005.08.014","article-title":"Ivermectin 20 years on: maturation of a wonder drug","volume":"21","author":"Geary","year":"2005","journal-title":"Trends Parasitol."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112647_bib77","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2007.08.023","article-title":"Ivermectin: 25 years and still going strong","volume":"31","author":"Omura","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112647_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in\u00a0vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"issue":"12","key":"10.1016\/j.ejmech.2020.112647_bib79","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1128\/AAC.00699-08","article-title":"Preclinical characteristics of the hepatitis C virus NS3\/4A protease inhibitor ITMN-191 (R7227)","volume":"52","author":"Seiwert","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib80","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/jm400164c","article-title":"Discovery of danoprevir (ITMN-191\/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3\/4A proteas","volume":"57","author":"Jiang","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib81","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40265-018-0960-0","article-title":"Danoprevir: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.112647_bib82","article-title":"First clinical study using HCV protease inhibitor danoprevir to treat naive and experienced COVID-19 patients","author":"Chen","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.ejmech.2020.112647_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102434","article-title":"The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China","volume":"109","author":"Yang","year":"2020","journal-title":"J.\u00a0Autoimmun."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib84","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41564-020-0690-4","article-title":"We shouldn\u2019t worry when a virus mutates during disease outbreaks","volume":"5","author":"Grubaugh","year":"2020","journal-title":"Nat. Microbiol."},{"issue":"9635","key":"10.1016\/j.ejmech.2020.112647_bib85","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib86","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib87","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2020.112647_bib88","article-title":"Fatal toxicity of chloroquine or hydroxychloroquine with metformin in mice","author":"Rajeshkumar","year":"2020","journal-title":"BioRxiv"},{"issue":"3","key":"10.1016\/j.ejmech.2020.112647_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharm. Res. Perspect."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2020.112647_bib90","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.112647_bib91","article-title":"Increasing host cellular receptor-angiotensin-converting enzyme 2 (ACE2) expression by coronavirus may facilitate 2019-nCoV infection","author":"Wang","year":"2020","journal-title":"BioRxiv"},{"issue":"10229","key":"10.1016\/j.ejmech.2020.112647_bib92","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib93","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cells9040909","article-title":"Exploring the relevance of senotherapeutics for the current SARS-CoV-2 emergency and similar future global health threats","volume":"9","author":"Malavolta","year":"2020","journal-title":"Cells"},{"issue":"7803","key":"10.1016\/j.ejmech.2020.112647_bib94","first-page":"311","article-title":"How does covid-19 kill? uncertainty hampers doctors\u2019 ability to choose treatments","volume":"580","author":"Ledford","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112647_bib95","first-page":"3","article-title":"Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools","author":"Fu","year":"2020","journal-title":"Virol. Sin."},{"issue":"1\u20133","key":"10.1016\/j.ejmech.2020.112647_bib96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.ejmech.2020.112647_bib97","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112647_bib98","author":"Cheminformatics"},{"issue":"1","key":"10.1016\/j.ejmech.2020.112647_bib99","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0006-2952(91)90006-Q","article-title":"Kinetics and thermodynamics of chloroquine and hydroxychloroquine transport across the human erythrocyte membrane","volume":"41","author":"Ferrari","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112647_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101647","article-title":"Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of the evidence","author":"Cao","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.ejmech.2020.112647_bib101","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112647_bib102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12936-017-1801-4","article-title":"Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety","volume":"16","author":"Chaccour","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2020.112647_bib103","series-title":"Hydroxychloroquine and Chloroquine Retinopathy in: Hydroxychloroquine and Chloroquine Retinopathy","first-page":"35","author":"Browning","year":"2014"},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib104","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00007691-198907000-00001","article-title":"Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine, Ther","volume":"11","author":"Titus","year":"1989","journal-title":"Drug Monit"},{"issue":"6","key":"10.1016\/j.ejmech.2020.112647_bib105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","article-title":"Bioavailability of hydroxychloroquine tablets in healthy volunteers, Brit","volume":"27","author":"Tett","year":"1989","journal-title":"J.\u00a0Clin. Pharm."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112647_bib106","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in\u00a0vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"issue":"6","key":"10.1016\/j.ejmech.2020.112647_bib107","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmol. Times"},{"key":"10.1016\/j.ejmech.2020.112647_bib108","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3332\/ecancer.2017.781","article-title":"Repurposing drugs in oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents","volume":"11","author":"Verbaanderd","year":"2017","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"10.1016\/j.ejmech.2020.112647_bib109","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0035-9203(02)90297-X","article-title":"The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy","volume":"96","author":"McGready","year":"2002","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","article-title":"Insights from nanomedicine into chloroquine efficacy against COVID-19","volume":"15","author":"Hu","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejmech.2020.112647_bib111","article-title":"A\u00a0systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J.\u00a0Crit. Care"},{"issue":"7","key":"10.1016\/j.ejmech.2020.112647_bib112","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cmi.2020.04.026","article-title":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study","volume":"26","author":"Lian","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112647_bib113","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2020.112647_bib114","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2020.112647_bib115","first-page":"12","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2020.112647_bib116","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In\u00a0vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2020.112647_bib117","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4269\/ajtmh.20-0271","article-title":"Ivermectin and novel coronavirus disease (COVID-19): keeping rigor in times of urgency","volume":"102","author":"Chaccour","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ejmech.2020.112647_bib118","article-title":"Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view","author":"Momekov","year":"2020","journal-title":"MedRxiv"},{"issue":"4","key":"10.1016\/j.ejmech.2020.112647_bib119","first-page":"668","article-title":"Recent discovery and development of inhibitors targeting coronaviruses, Drug Discov","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Today Off."},{"key":"10.1016\/j.ejmech.2020.112647_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and covid-19 therapeutics","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib121","first-page":"810","article-title":"Advance of promising targets and agents against 2019-nCoV in China, Drug Discov","volume":"25","author":"Duan","year":"2020","journal-title":"Today Off."},{"key":"10.1016\/j.ejmech.2020.112647_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.04.017","article-title":"Hydroxychloroquine and ivermectin: a synergistic combination for COVID-19 chemoprophylaxis and\/or treatment?","author":"Patr\u00ec","year":"2020","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"key":"10.1016\/j.ejmech.2020.112647_bib123","article-title":"Clinical characteristics of Coronavirus Disease 2019 in Hangzhou, China: the combination of lopinavir\/ritonavir, interferon, and arbidol may be a well choice for antiviral therapy in common cases","author":"Yu","year":"2020","journal-title":"Res. Square"},{"key":"10.1016\/j.ejmech.2020.112647_bib124","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A\u00a0trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112647_bib125","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J.\u00a0Infect."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112647_bib126","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study","volume":"81","author":"Deng","year":"2020","journal-title":"J.\u00a0Infect."},{"key":"10.1016\/j.ejmech.2020.112647_bib127","doi-asserted-by":"crossref","DOI":"10.1111\/bph.15072","article-title":"Current pharmacological treatments for COVID-19: what\u2019s next?","author":"Scavone","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112647_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","author":"McKee","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2020.112647_bib129","article-title":"Remdesivir: a review of its discovery and development leading to human clinical trials for treatment of COVID-19","author":"Eastman","year":"2020","journal-title":"Preprints"},{"key":"10.1016\/j.ejmech.2020.112647_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2020.112647_bib131","article-title":"A\u00a0Preliminary Study on the Reproductive Toxicity of GS-5734 on Male Mice","author":"Fan","year":"2020","journal-title":"bioRxiv"},{"issue":"10236","key":"10.1016\/j.ejmech.2020.112647_bib132","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(20)31023-0","article-title":"Remdesivir for COVID-19: challenges of underpowered studies","volume":"395","author":"Norrie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2020.112647_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.ejmech.2020.112647_bib135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-020-02799-8","article-title":"Tilorone: a broad-spectrum antiviral invented in the USA and commercialized in Russia and beyond","volume":"37","author":"Ekins","year":"2020","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2020.112647_bib136","first-page":"87","article-title":"Drug targets for COVID-19 therapeutics: ongoing global efforts","volume":"45","author":"Saxena","year":"2020","journal-title":"J.\u00a0Bio. Sci."},{"key":"10.1016\/j.ejmech.2020.112647_bib137","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: drug targets and potential treatments","author":"Gil","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112647_bib138","first-page":"1","article-title":"Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ejmech.2020.112647_bib139","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1016\/j.jmb.2020.04.009","article-title":"Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically-sensitive activation loop","volume":"432","author":"Jaimes","year":"2020","journal-title":"J.\u00a0Mol. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2020.112647_bib140","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1021\/acs.jpclett.0c00571","article-title":"Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks","volume":"11","author":"Zhang","year":"2020","journal-title":"J.\u00a0Phys. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112647_bib141","article-title":"Attacking the SARS-CoV-2 replication machinery with the pathogen box\u2019s molecules","author":"Osorio-Mogollon","year":"2020","journal-title":"ChemRxiv. Preprint."},{"key":"10.1016\/j.ejmech.2020.112647_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.034","article-title":"The global phosphorylation landscape of SARS-CoV-2 infection","author":"Bouhaddou","year":"2020","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejmech.2020.112647_bib143","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112647_bib145","article-title":"Dexamethasone for COVID-19? Not so fast","volume":"34","author":"Theoharides","year":"2020","journal-title":"J.\u00a0Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.ejmech.2020.112647_bib146","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2020.112647_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31174-0","article-title":"Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?","author":"Funck-Brentano","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2020.112647_bib148","article-title":"Covid-19: 146 researchers raise concerns over chloroquine study that halted WHO trial","volume":"369","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2020.112647_bib149","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342030619X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342030619X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:14:23Z","timestamp":1759328063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342030619X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":144,"alternative-id":["S022352342030619X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112647","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112647"}}